Ubs Group Ag Abb Vie Inc. Put Options Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

Put Options

31 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $29.9 Million - $36.3 Million	182,200 Added 17.06%	1,250,400 $247 Million
Q2 2024 Aug 13, 2024	SELL	$154.79 - $180.76 $64.9 Million - $75.8 Million	-419,100 Reduced 28.18%	1,068,200 $183 Million
Q1 2024 May 13, 2024	SELL	$159.82 - $182.1 $41 Million - $46.7 Million	-256,648 Reduced 14.72%	1,487,300 $271 Million
Q4 2023 Feb 09, 2024	BUY	$137.6 - $154.97 $50.2 Million - $56.6 Million	364,948 Added 26.46%	1,743,948 $270 Million
Q3 2023 Nov 09, 2023	BUY	$133.59 - $154.65 $53.1 Million - $61.5 Million	397,500 Added 40.5%	1,379,000 $206 Million
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $7.66 Million - $9.53 Million	-57,800 Reduced 5.56%	981,500 $132 Million
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $58.1 Million - $66.9 Million	-401,500 Reduced 27.87%	1,039,300 $166 Million
Q4 2022 Feb 08, 2023	BUY	$138.31 - $165.87 $27.3 Million - $32.7 Million	197,100 Added 15.85%	1,440,800 $233 Million
Q3 2022 Nov 10, 2022	SELL	$134.21 - $153.93 $9.05 Million - $10.4 Million	-67,400 Reduced 5.14%	1,243,700 $167 Million
Q2 2022 Aug 10, 2022	SELL	$137.62 - $174.96 $21.1 Million - $26.8 Million	-153,200 Reduced 10.46%	1,311,100 $201 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $147 Million - $183 Million	-1,116,174 Reduced 43.25%	1,464,300 $237 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $98.9 Million - $125 Million	920,338 Added 55.44%	2,580,474 $349 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $29 Million - $32.9 Million	272,800 Added 19.66%	1,660,136 $179 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $34.8 Million - $38.8 Million	330,613 Added 31.29%	1,387,336 $156 Million
Q1 2021 May 12, 2021	SELL	$102.3 - $112.62 $39.3 Million - $43.2 Million	-383,879 Reduced 26.65%	1,056,723 $114 Million
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $20.8 Million - $28.1 Million	258,821 Added 21.9%	1,440,602 $154 Million
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $12.5 Million - $14.7 Million	-145,418 Reduced 10.96%	1,181,781 $104 Million
Q2 2020 Jul 31, 2020	SELL	$73.37 - $98.18 $37.8 Million - $50.6 Million	-515,101 Reduced 27.96%	1,327,199 $130 Million
Q1 2020 May 01, 2020	BUY	$64.5 - $97.79 $18.3 Million - $27.8 Million	284,200 Added 18.24%	1,842,300 $140 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $42.8 Million - $53.5 Million	593,000 Added 61.44%	1,558,100 $138 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $29.7 Million - $35.7 Million	471,700 Added 95.6%	965,100 $73.1 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $59.1 Million - $75.6 Million	-900,100 Reduced 64.59%	493,400 $35.9 Million
Q1 2019 May 14, 2019	BUY	$77.14 - $90.79 $81.5 Million - $95.9 Million	1,056,600 Added 313.62%	1,393,500 $112 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $778,500 - $960,100	-10,000 Reduced 2.88%	336,900 $31.1 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $3.07 Million - $3.41 Million	34,500 Added 11.04%	346,900 $32.8 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $1.98 Million - $2.34 Million	-22,000 Reduced 6.58%	312,400 $28.9 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $19.3 Million - $25.8 Million	-209,600 Reduced 38.53%	334,400 $31.7 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $3.04 Million - $3.33 Million	33,900 Added 6.65%	544,000 $52.6 Million
Q3 2017 Nov 14, 2017	SELL	$69.85 - $89.22 $803,274 - $1.03 Million	-11,500 Reduced 2.2%	510,100 $45.3 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-194,600 Reduced 27.17%	521,600 $37.8 Million
Q1 2017 Nov 14, 2017	BUY	N/A	716,200	716,200 $46.7 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account